Group 1: Shareholder and Stock Information - The company’s directors and senior management can transfer up to 25% of their shares annually during their term and six months after, based on the last trading day of the previous year [2][3] - The latest number of shareholders will be disclosed in the company's regular reports [3][4] Group 2: Production and Operations - The Xinjiang factory has commenced production [3][6] - The company is closely monitoring industry trends and is open to asset acquisitions if opportunities arise, adhering to legal and regulatory requirements [3][6] Group 3: Financial Performance and Revenue - The AI server business generated revenue of 53.98 million yuan in the first half of 2025 [5][6] - The company aims to achieve a main revenue target of 300 million yuan this year [6][7] Group 4: Business Strategy and Future Plans - The company is focusing on two main business areas: pharmaceutical manufacturing and AI server solutions [7] - There are no current plans for major asset restructuring or acquisitions, but future developments will be disclosed as per regulations [7][8] Group 5: AI Server Business Development - The AI server business is in its early stages, aiming to provide high-performance servers tailored to customer needs [5][6] - The company is positioning itself as a provider of general AI computing infrastructure, not limited to the pharmaceutical sector [7][8]